- Home
- PLRX vs FAX Comparison
PLRX vs FAX Comparison
Compare PLRX & FAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLRX | FAX |
|---|---|---|
| Founded | 2015 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.3M | 632.9M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | PLRX | FAX |
|---|---|---|
| Price | $1.23 | $15.26 |
| Analyst Decision | Hold | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $3.79 | N/A |
| AVG Volume (30 Days) | ★ 1.9M | 833.6K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 12.09% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.10 | $2.33 |
| 52 Week High | $14.30 | $2.84 |
Technical Indicators
Market Signals| Indicator | PLRX | FAX |
|---|---|---|
| Relative Strength Index (RSI) | 34.56 | 47.12 |
| Support Level | $1.19 | $15.20 |
| Resistance Level | $1.30 | $15.32 |
| Average True Range (ATR) | 0.11 | 0.12 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 12.50 | 45.76 |
Price Performance
Historical ComparisonAbout PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About FAX abrdn Asia-Pacific Income Fund Inc.
Aberdeen Asia-pacific Income Fund Inc is a United States-based closed-end, non-diversified management investment company. Its principal investment objective is to seek current income along with capital appreciation. The fund invests in Asian debt securities, Australian debt securities, European debt securities and others.